BRIEF published on 03/26/2024 at 10:24, 7 months 26 days ago USU Software AG Announces Recall of Treasury Shares Treasury Shares USU Software AG Corporate Announcement Share Recall Subscribed Capital
PRESS RELEASE published on 03/26/2024 at 10:19, 7 months 26 days ago EQS-Adhoc: USU Software AG: Recall of Treasury Shares USU Software AG recalls all 487,286 treasury shares, maintaining unchanged subscribed capital. Each remaining share has a notional value of EUR 1.048 Treasury Shares USU Software AG Share Recall Subscribed Capital Notional Value
BRIEF published on 03/14/2024 at 09:06, 8 months 8 days ago USU Software AG Plans Delisting, NuWays AG Adjusts Recommendation to HOLD NuWays AG Investment Recommendation Stock Valuation Delisting USU Software AG
PRESS RELEASE published on 03/14/2024 at 09:01, 8 months 8 days ago Original-Research: USU Software AG (von NuWays AG): HOLD USU Software AG announces delisting intention supported by majority shareholder AUSUM. Offer price expected around €17.00 per share. Analyst advises holding shares HOLD Recommendation Offer Price USU Software AG Delisting Intention Majority Shareholder
BRIEF published on 03/12/2024 at 18:26, 8 months 9 days ago USU Software AG Announces 2023 Results and Strategic Shifts Including Delisting Plans Delisting USU Software AG Financial Results 2023 Strategic Expansion Investment In AI And FinOps
PRESS RELEASE published on 03/12/2024 at 18:21, 8 months 9 days ago EQS-Adhoc: USU Software AG Announces Provisional Figures for 2023, Expansion of Product Business, and Delisting Plans USU Software AG confirms 2023 sales of EUR 132 million and delisting plans to explore strategic options for future growth and investment Strategic Options USU Software AG 2023 Sales Delisting Plans Product Business Expansion
BRIEF published on 03/07/2024 at 09:11, 8 months 15 days ago USU Software AG Anticipates Positive Annual Report Driven by License Sales Recovery and SaaS Growth Financial Performance Investment Recommendation USU Software AG SaaS Growth License Sales
PRESS RELEASE published on 03/07/2024 at 09:06, 8 months 15 days ago Original-Research: USU Software AG (von NuWays AG): BUY NuWays AG classified under USU Software AG with a buy recommendation. Q4 preview indicates sequential improvements in sales driven by license recovery and growing SaaS sales. Analysis available at www.more-ir.de Buy Recommendation NuWays AG USU Software AG Q4 Preview License Recovery
PRESS RELEASE published on 02/07/2024 at 08:12, 9 months 15 days ago USU receives international award as Liferay Partner of the Year USU receives 'Liferay Partner of the Year' award for EMEA region, showcasing expertise in delivering digital solutions on the Liferay platform, following ceremony in Rome USU Software AG Liferay Partner Of The Year Digital Experience Solutions Liferay Platform EMEA
PRESS RELEASE published on 11/09/2023 at 13:43, 1 year ago US Technology Company Chooses USU Software Asset Management
Published on 11/22/2024 at 09:00, 20 minutes ago Industrial Software Company mlean Celebrates 10 Years of Continuous Improvement
Published on 11/22/2024 at 00:00, 9 hours 20 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 11 hours 15 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 11 hours 30 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 13 hours 5 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 06:58, 1 day 2 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 14 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 15 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 15 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 2 days 1 hour ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
